TCA IR 40 mg

DRUG3 trials

Sponsors

Pacira Pharmaceuticals, Inc

Conditions

Osteoarthritis of the KneePost-traumatic Osteoarthritis of the KneeType 2 Diabetes Mellitus

Phase 2

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

CompletedNCT02003365

Pacira Pharmaceuticals, IncOsteoarthritis of the Knee

Start: 2013-11-30End: 2014-04-30Updated: 2024-01-24

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

TerminatedNCT02468583

Pacira Pharmaceuticals, IncPost-traumatic Osteoarthritis of the Knee

Start: 2015-02-28End: 2016-07-31Updated: 2024-01-24

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

CompletedNCT02762370

Pacira Pharmaceuticals, IncOsteoarthritis of the Knee, Type 2 Diabetes Mellitus

Start: 2016-04-30End: 2016-11-30Updated: 2024-01-24

Related Papers

Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study

Lara D. Veeken2018-08-0639 citations